{"id":1538,"date":"2026-11-04T08:33:56","date_gmt":"2026-11-04T08:33:56","guid":{"rendered":"https:\/\/admit-therapeutics.com\/?p=1538"},"modified":"2026-11-04T08:37:38","modified_gmt":"2026-11-04T08:37:38","slug":"admit-therapeutics-presents-the-map-ad-test-at-the-13th-argentine-congress-of-clinical-laboratory-quality-calilab-2026","status":"publish","type":"post","link":"https:\/\/admit-therapeutics.com\/en\/admit-therapeutics-presents-the-map-ad-test-at-the-13th-argentine-congress-of-clinical-laboratory-quality-calilab-2026\/","title":{"rendered":"ADmit Therapeutics presents the MAP-AD\u00a0Test at the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Barcelona (Spain), November 4, 2026. ADmit Therapeutics will participate in the <strong>Neurogenetics Conference organized by MANLAB<\/strong> within the framework of the <strong>13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026)<\/strong>.\u00a0Dr.\u00a0Carla Trapero will present the <strong>MAP-AD Test<\/strong>,\u00a0the only regulatory-approved blood-based prognostic test (IVDR &#8211; EU 2017\/746) that predicts progression to Alzheimer\u2019s dementia in patients with mild cognitive impairment<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For more information:&nbsp;<strong>https:\/\/diagnosticsnews.com\/especialidades-medicas\/jornadas-de-neurogenetica-manlab-marite-garimaldi-anticipa-los-avances-en-neurogenetica-y-alzheimer-que-manlab-presentara-en-calilab-2026<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Barcelona (Spain), November 4, 2026. ADmit Therapeutics will participate in the Neurogenetics Conference organized by MANLAB within the framework of the 13th Argentine Congress of Clinical Laboratory Quality (CALILAB 2026).\u00a0Dr.\u00a0Carla Trapero will present the MAP-AD Test,\u00a0the only regulatory-approved blood-based prognostic test (IVDR &#8211; EU 2017\/746) that predicts progression to Alzheimer\u2019s dementia in patients with mild [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1538","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/comments?post=1538"}],"version-history":[{"count":2,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1538\/revisions"}],"predecessor-version":[{"id":1542,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/posts\/1538\/revisions\/1542"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/media?parent=1538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/categories?post=1538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admit-therapeutics.com\/en\/wp-json\/wp\/v2\/tags?post=1538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}